|
Press Releases |
|
|
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
Thursday, July 11, 2024 |
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「LEQEMBI」(レカネマブ)が香港においてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性 アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(香港製品名:「樂意保(R)」、一般名:レカネマブ)について、香港衛生署(Department of Health)より新薬承認を取得したことをお知らせします。 more info >> |
|
Tuesday, July 2, 2024 |
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
Friday, June 28, 2024 |
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
Friday, June 21, 2024 |
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
Monday, June 10, 2024 |
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(一般名:レカネマブ)について、静注(IV)維持投与に関する生物製剤承認一部変更申請(sBLA)が米国食品医薬品局(FDA)に受理されたことをお知らせします。 more info >> |
|
Monday, June 3, 2024 |
|
Eisai Named to List of The Time 100 Most Influential Companies |
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Annual fashion spotlight CENTRESTAGE draws more than 8,500 buyers
Sept 7, 2024 20:19 HKT/SGT
|
|
|
TANAKA Precious Metals Announces Executive Appointments
Sept 7, 2024 3:00 JST
|
|
|
Amazfit Launches T-Rex 3, the Ultimate Adventure Companion
Sept 6, 2024 20:00 HKT/SGT
|
|
|
周大福人寿2024年上半年 首年年化保费收入按年上升33% 持续强劲增长势头
Sept 6, 2024 17:01 HKT/SGT
|
|
|
周大福人壽2024年上半年 首年年化保費收入按年上升33% 持續強勁增長勢頭
Sept 6, 2024 16:42 HKT/SGT
|
|
|
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sept 6, 2024 16:34 JST
|
|
|
GTJAI Receives Multiple Awards in Bond Connect 2024 Awards
Sept 6, 2024 15:32 HKT/SGT
|
|
|
國泰君安國際榮獲2024年度「債券通」多項殊榮 彰顯互聯互通業務實力
Sept 6, 2024 15:25 HKT/SGT
|
|
|
国泰君安国际荣获2024年度“债券通”多项殊荣 彰显互联互通业务实力
Sept 6, 2024 15:16 HKT/SGT
|
|
|
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sept 6, 2024 15:10 JST
|
|
|
Reopening of CENTRESTAGE, Hong Kong Watch & Clock Fair and Salon de TIME
Sept 6, 2024 11:10 HKT/SGT
|
|
|
transport logistic and air cargo Southeast Asia: Fueling Regional Economic Growth
Sept 6, 2024 10:09 HKT/SGT
|
|
|
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sept 6, 2024 9:26 JST
|
|
|
How Much Do Vegan Diets Improve the Health of Dogs?
Sept 6, 2024 07:00 HKT/SGT
|
|
|
Taiwan Excellence Unveils Pioneering Medtech Innovation at Medical Fair Asia 2024
Sept 5, 2024 23:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|